Search research articles
Contact Us
Filters
Showing results (241-250 of 418) with videos related to
Page
of 42
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 8, 2022
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
The Lancet. Oncology
|
April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Olivier Mir, Claire Cropet, Maud Toulmonde, et al.
JAMA Oncology
|
March 31, 2022
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
Robin L Jones, Vinod Ravi, Andrew S Brohl, et al.
Journal for Immunotherapy of Cancer
|
June 8, 2023
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
Guy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 25, 2009
Oral cavity squamous cell carcinoma in 260 patients aged 80years or more
Cécile Ortholan, Antoine Lusinchi, Antoine Italiano, et al.
Plos One
|
September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)
Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
British Journal of Clinical Pharmacology
|
April 1, 2020
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
Christian Rolfo, Nicolas Isambert, Antoine Italiano, et al.
The Lancet. Oncology
|
November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
Lancet (London, England)
|
February 15, 2016
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant Chawla, Robert G Maki, et al.
Page
of 42
Search research articles
Search
Showing results (241-250 of 418) with videos related to
Sort By:
Page
of 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2021
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Maud Toulmonde, Mehdi Brahmi, Antoine Giraud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 8, 2022
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
The Lancet. Oncology
|
April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Olivier Mir, Claire Cropet, Maud Toulmonde, et al.
JAMA Oncology
|
March 31, 2022
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
Robin L Jones, Vinod Ravi, Andrew S Brohl, et al.
Journal for Immunotherapy of Cancer
|
June 8, 2023
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
Guy Travis Clifton, Mace Rothenberg, Paolo Antonio Ascierto, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 25, 2009
Oral cavity squamous cell carcinoma in 260 patients aged 80years or more
Cécile Ortholan, Antoine Lusinchi, Antoine Italiano, et al.
Plos One
|
September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)
Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
British Journal of Clinical Pharmacology
|
April 1, 2020
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
Christian Rolfo, Nicolas Isambert, Antoine Italiano, et al.
The Lancet. Oncology
|
November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
Lancet (London, England)
|
February 15, 2016
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant Chawla, Robert G Maki, et al.
Page
of 42